IASLC Lung Cancer News (ILCN), March 2024
ILCN | English
Image For Activity Cover
Availability
On-Demand
Cost
$0.00
Credit Offered
No Credit Offered
In this Issue:
  • Regulating Artificial Intelligence
  • Experts Debate Addition of Frontline Chemotherapy for EGFR+ NSCLC
  • Should Biomarkers Be Used in the Clinical Management of ES-SCLC?
  • US FDA Grants Breakthrough Therapy Designation for Novel TKI Targeting HER2, EGFR
  • Food as Medicine: Research Aims to Understand the Power of Nutrition in Treating Cancer
  • Debaters Argue Merits of Surgery in Malignant Meso in Light of MARS2 Data
  • Can pCR Be an Early Clinical Trial Endpoint? Initiative Aims to Answer That Question
  • Words Matter: Coping with Misinformation in Healthcare
  • US FDA Approves Frontline Amivantamab Combination for Patients with EGFR exon 20 Insertion-mutated NSCLC
IASLC Lung Cancer News (ILCN) is the offical news source of the only global association dedicated to the multidisciplinary study of lung cancer, published bimonthly by the International Association for the Study of Lung Cancer (IASLC). 

Click here to link to Submission Guidelines.
Powered By